Skip header and navigation

Refine By

6 records – page 1 of 1.

[Morbidity and treatment of penile cancer (based on data from the Moscow Municipal Oncology Dispensary)].

https://arctichealth.org/en/permalink/ahliterature243720
Source
Vopr Onkol. 1982;28(1):66-8
Publication Type
Article
Date
1982
Author
B P Matveev
I D Vasil'eva
V K Zaseev
D T Gopadze
Source
Vopr Onkol. 1982;28(1):66-8
Date
1982
Language
Russian
Publication Type
Article
Keywords
Adult
Aged
Cancer Care Facilities
Hospitals, Special
Humans
Male
Middle Aged
Moscow
Neoplasm Staging
Penile Neoplasms - epidemiology - therapy
Abstract
Penis carcinoma morbidity in the city of Moscow in 1973-1979 was 0.5 per 100,000 of male population, most of the patients being older than 60 years. On primary application, stage I of the disease was identified in 17.5%; stage II -- 42.9%; stage III -- 34.9% and stage IV in 4.7% of patients. Therefore, advanced tumors were found in 39.6% of patients. Combined treatment was given to 31.6%, radiation alone -- 37.5%, surgery -- 21.3% and symptomatic therapy -- 7.4% of cases. Three patients refused to take therapy.
PubMed ID
7064397 View in PubMed
Less detail

[Results of a 5-year screening for prostatic cancer].

https://arctichealth.org/en/permalink/ahliterature186371
Source
Urologiia. 2003 Jan-Feb;(1):6-10
Publication Type
Article
Author
B P Matveev
L E Komarova
B V Bukharkin
V N Sholokhov
Z G Kadagidze
N L Cheban
P I Lepédatu
V M Shelepova
N V Perederii
N N Lomakin
Source
Urologiia. 2003 Jan-Feb;(1):6-10
Language
Russian
Publication Type
Article
Keywords
Adult
Age Factors
Aged
Aged, 80 and over
Alcohol drinking - epidemiology
Biopsy
Humans
Male
Mass Screening
Middle Aged
Moscow - epidemiology
Prostate - pathology
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood - diagnosis - epidemiology - mortality - pathology - ultrasonography
Russia - epidemiology
Sensitivity and specificity
Smoking - epidemiology
Time Factors
Abstract
The results of 5-year screening (1996-2000) for prostatic cancer in 1129 males 40 to 80 years of age are presented. The examination included: measurement of blood levels of prostate-specific antigen (PSA), finger rectal examination, transrectal ultrasonic examination (TRUE) and, on demand, biopsy of the prostatic gland. Prostatic cancer was diagnosed in 1.5, 2.2 and 16% patients having PSA levels of 0-4.0, 4.0-10.0 and 10.0-30.0% ng/ml, respectively. At finger rectal examination prostatic cancer was suspected in 8% examinees, only in 33% of them the diagnosis was verified morphologically. By TRUE evidence 7% examinees were suspected and in 44.3% of them prostatic cancer was confirmed. Thus, biopsy proved necessary in 172 cases of 1129 examinees. In 64 (5.7%) males prostatic cancer was diagnosed and confirmed. Early prostatic cancer in the screened men and those consulted in the outpatient department of the National Cancer Research Center was detected in 77.7 and 22% men, respectively. The conclusion is made that men over 50 years of age should undergo prophylactic examination of the prostatic gland once a year.
PubMed ID
12621958 View in PubMed
Less detail

[Statistics of oncourologic diseases in Russia in 1996].

https://arctichealth.org/en/permalink/ahliterature187762
Source
Urol Nefrol (Mosk). 1999 Mar-Apr;(2):3-10
Publication Type
Article
Author
E M Aksel'
B P Matveev
Source
Urol Nefrol (Mosk). 1999 Mar-Apr;(2):3-10
Language
Russian
Publication Type
Article
Keywords
Female
Humans
Male
Russia - epidemiology
Survival Rate
Urogenital Neoplasms - epidemiology - mortality - pathology
Abstract
The trends in male urinary and genital cancer morbidity and mortality are specified. Statistics on separate malignant urological diseases are provided. In 1996 the number of patients with cancer of male urinary and sex organs reached 31.700. A growth in morbidity was due rather to a higher risk to develop the disease than because of changes in the population age. Urological cancer reduces mean life span of Russian population by 2 months, and the patients' life terminates 10-19 years earlier. Financial losses due to deaths of urological cancer stand as high as 197 million roubles as estimated in 1990 prices.
PubMed ID
12434431 View in PubMed
Less detail

[Statistics on oncological urologic diseases in Russia].

https://arctichealth.org/en/permalink/ahliterature213915
Source
Urol Nefrol (Mosk). 1995 Nov-Dec;(6):2-6
Publication Type
Article
Author
V V Dvoirin
B P Matveev
E M Aksel'
Source
Urol Nefrol (Mosk). 1995 Nov-Dec;(6):2-6
Language
Russian
Publication Type
Article
Keywords
Adult
Aged
Data Interpretation, Statistical
Female
Humans
Incidence
Male
Middle Aged
Morbidity - trends
Mortality - trends
Prevalence
Russia - epidemiology
Sex Distribution
Urogenital Neoplasms - epidemiology
World Health
Abstract
Incidence rate of male urogenital cancer has increased for 1975-1993 by 138.7% reaching 27,700. The disease-specific trends in prevalence, morbidity and mortality are outlined. The rise in urogenital cancer incidence is attributed to higher risk to develop the disease rather than to growing percentage of the elderly among overall population. Mean lifespan of Russian population due to urological cancer mortality is cut by 2 months. Fatal cases live by 11-19 years less than healthy subjects. Economical losses because of deaths of urological cancer make up 187.3 million rubles in 1990 prices.
PubMed ID
8686116 View in PubMed
Less detail

[The results of the surgical treatment of bladder cancer patients].

https://arctichealth.org/en/permalink/ahliterature209095
Source
Urol Nefrol (Mosk). 1997 Mar-Apr;(2):25-8
Publication Type
Article
Author
B P Matveev
K M Figurin
Source
Urol Nefrol (Mosk). 1997 Mar-Apr;(2):25-8
Language
Russian
Publication Type
Article
Keywords
Cancer Care Facilities
Combined Modality Therapy
Cystectomy - methods
Female
Follow-Up Studies
Humans
Incidence
Male
Middle Aged
Moscow - epidemiology
Neoplasm Recurrence, Local - epidemiology - pathology - surgery
Neoplasm Staging
Postoperative Complications - epidemiology
Urinary Bladder Neoplasms - epidemiology - pathology - surgery
Urinary Diversion - methods
Abstract
101 patients with cancer of the bladder were operated in the Moscow Cancer Research Center from 1990 to 1995. Cystectomy with varying urinary bypass was made in 49 patients. 52 patients were subjected to bladder resection. The former developed recurrences in 28.9%, the latter in 62% of the patients. Recurrences after the resections were primarily local. 5-year survival of transient-cell bladder carcinoma patients after cystectomy made up 68.2%, after the resection 80.7%. The authors hold that both operations are applicable, but they have specific indications.
PubMed ID
9206878 View in PubMed
Less detail

[The statistics on malignant neoplasms of the urinary and male genital organs in 1987 in the USSR]

https://arctichealth.org/en/permalink/ahliterature25306
Source
Urol Nefrol (Mosk). 1990 Jan-Feb;(1):42-5
Publication Type
Article
Author
V V Dvoirin
B P Matveev
E M Aksel'
S F Zobnina
Source
Urol Nefrol (Mosk). 1990 Jan-Feb;(1):42-5
Language
Russian
Publication Type
Article
Keywords
Age Factors
English Abstract
Genital Neoplasms, Male - diagnosis - epidemiology - mortality
Humans
Incidence
Male
USSR - epidemiology
Urologic Neoplasms - diagnosis - epidemiology - mortality
Abstract
The USSR statistics on malignant neoplastic diseases of the urinary system and male sexual organs which comprised 5.7 per cent in the total mortality was presented for the first time. More than a 50 per cent increment in the death rate from these tumors was documented between 1975 and 1987. Annually, prostatic carcinoma is diagnosed in almost 10 thousand patients and cancer of the urinary bladder in 15 thousand patients. Maximal prevalence of the disease has been recorded in the Baltic republics, the Ukraine and Byelorussia. The detection rate of the aforementioned diseases, Stages I-II, is about 40 per cent. The estimate revealed that the total number of the registered oncological patients was 100 thousand persons. The problems in organization of the oncological care system, material and technical supplies and professional training should be considered.
PubMed ID
2336757 View in PubMed
Less detail

6 records – page 1 of 1.